For Requesting a Sample Copy of This Report, Please Visit: http://www.qyresearchreports.us/request-sample/global-drugs-for-vulvovaginal-candidiasis-market-research-report-2017
What is Vulvovaginal Candidiasis?
Vulvovaginal candidiasis is also termed as yeast infection, or vaginal thrush, it is a common vaginal infection. This condition is a result of excessive fungus, or yeast-like germ that leads to severe irritation. Fungi or yeast are a usual part of the vagina, however when these fungi multiply in quantity, it can lead to infection. Vulvovaginal candidiasis is caused by C. albicans, nevertheless it can in rare cases be caused due to other yeast or Candida sp. A few of the most common symptom is itching near the vulva, which can be very severe. It is not determined as a sexually transmitted infection. But, the prevalence might be more often in those who are more sexually active. Some of the other symptoms of this condition include, thick and white vaginal discharge which might not smell bad, burning sensation while passing urine, painful sex, and reddish inflamed area surrounding the vagina. All of these mentioned symptoms often get worse just prior to a woman due to getting her periods. Study done on vulvovaginal candidiasis market, states that this condition of the vagina is linked with dermatitis of the vulva which is an itchy rash. Some of the other names for vulvovaginal candidiasis are monilia, vulvovaginal candidosis, or genital candidiasis. The imbalance in the level of Candida occurs when the normal acidity or pH level of the vagina alters or when there is an alteration in hormonal balance.
Several risk factors associated are pregnancy, diabetes, antibiotics, and HIV/AIDS. Besides, wearing tight clothes without any breathing space, material of the underwear and personal hygiene might also play a key role. Vulvovaginal candidiasis is diagnosed by testing a small sample of the vaginal discharge. Since the symptom this condition has is very similar to chlamydia, gonorrhoea, or sexually transmitted diseases, testing is of utmost significance. Approximately, 75 percent of women have at least one experience of vulvovaginal candidiasis, and nearly 40 to 45 percent will experience twice. Based on various clinical presentations, host factors, microbiology, and response of therapy, vulvovaginal candidiasis is also characterized as either complicated or uncomplicated. Out of which nearly 10 to 20 percent of women, have complicated version of this condition, which needs therapeutics and diagnostics considerations.
Who is prone to Vulvovaginal Candidiasis?
As already mentioned apart from women, on rare cases men also tend to get genital candidiasis. This condition has prevalence in individuals with immunocompromised systems. Apart from pregnancy and diabetes, prolonged use of corticosteroid medications and enduring use of broad-spectrum antibiotics, can also put women at high risk of acquiring this condition.
There are many antifungal medications available to treat this condition. Antifungal vaginal creams or suppositories are widely used. The course of the treatment can vary from two to seven days depending upon the severity of the condition. Mild to moderate conditions can be treated with just a single dose of oral antifungal medicines. These medication generally have an 80 to 90 percent success rate, however a few women might have resistant infections. Healthcare experts also recommend using cotton underwear which assists in reducing the risk of yeast infection. For women who suffer from this infection for more than thrice a year, evidences recommend intravaginal or oral probiotics which might help to avoid frequent infections.
To Know More About This Report, Click Here: http://www.qyresearchreports.us/market-analysis/global-drugs-for-vulvovaginal-candidiasis-market-research-report-2017
Table of Contents
Global Drugs for Vulvovaginal Candidiasis Market Research Report 2017
1 Drugs for Vulvovaginal Candidiasis Market Overview
1.1 Product Overview and Scope of Drugs for Vulvovaginal Candidiasis
1.2 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.1 Global Production Market Share of Drugs for Vulvovaginal Candidiasis by Type in 2015
1.3 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3.1 Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application in 2015
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Drugs for Vulvovaginal Candidiasis Market by Region
1.4.1 North America Status and Prospect (2012-2022)
1.4.2 Europe Status and Prospect (2012-2022)
1.4.3 China Status and Prospect (2012-2022)
11323 136th Ave East
Puyallup, Wa 98374
Email – Sales@Qyresearchreports.Us